The thing a lot of longs here are forgetting is, thanks to the panel's vote, about the best you can hope for now is a conditional approval, (with a CRL being most likely outcome, but for the sake of this thread's silly question, let's assume they get conditional approval). In the unlikely scenario this gets FDA approved, it will probably be an approval that limits the drugs availaiblity and/or requiring a phase IV to go along with it. That obviously puts a huge anchor on the "pop", so-to-speak.
And keep in mind this doesn't even factor in the issues regarding patents and license control with other big pharma players (MRK, GSK, PFE) that were weights on the stock from before and are all still unresolved and could eat away any DVAX profits from Heplisav for some time, if not infinitely.
IMO, even if DVAX gets approval, the stock is most likely already overpriced even now at $3. I think if they get approved, it will drop to $2 - 2.50 range. If CRL, $0.75 - $1.25.